The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:
----------
Byotrol PLC - Chester, England-based developer of antimicrobial technologies and products - For the year ended March 31, expects sales of £6.3 million, comprising of £5.2 million from product sales and £1.1 million from intellectual property sales and royalties. Anticipates positive adjusted earnings before interest, tax, depreciation and amortisation before expectational items. Chief Executive David Traynor says: ‘We are pleased to confirm that our results for the past year will meet expectations as described in our trading update of early March.’ Since year-end, company signs two ‘significant’ new IP agreements. Byotrol will publish its full-year results before the end of August.
----------
Mobile Streams PLC - London-based mobile content provider - Signs two partnerships deals to help expand its portfolio of NFT licences and to grow revenue opportunities from its recently announced PUMAS transaction. The partnerships with PAS Kisisel Asistanlik Hizmetleri Ltd and Andrea Olmedo Lopez will progress an additional 30 active deals in the company’s NFT licence pipeline to an advanced stage, Mobile Streams explains. Mobile Streams will pay the agencies in shares totalling £500,000.
----------
Kavango Resources PLC - London-based mineral explorer focused on Botswana - Identifies a cluster of three electromagnetic conductors within target area B in the Kalahari Suture Zone, Botswana. Chief Executive Ben Turney says: ‘These are some of the most outstanding exploration results Kavango has delivered in the Kalahari Suture Zone. We now have 3 significant drill targets, in close proximity to one another, in our hunt for ’Norilsk Model’ nickel/copper/platinum group element ore bodies.’
----------
Kinovo PLC - London-based property services company focused on safety and regulatory compliance, land regeneration and energy efficiency - Reports its three visible revenue for its continuing business have increased to £139 million at March 31 from £105 million at the same time a year prior. Notes additional wins totalling £3 million post-period end and revenue growth of 28% in the two months ending May 31 compared to the previous year. Adjusted earnings before interest, tax, depreciation and amortisation grows 35% in the same two months compared to a year prior. Expects to report revenue from continuing operations of £53.3 million in the year ended March 31, up 35% from £39.4 million a year prior, with adjusted Ebitda doubling to £4.2 million from £2.1 million. Company adds it is working with consultants to establish the costs to complete construction projects with former subsidiary DCB. Calls the talks ‘productive and encouraging’.
----------
Bivictrix Therapeutics PLC - Cheshire, England-based biotechnology company - Reports ‘significant’ progress with its lead caner therapy candidate, BVX001. Company says it is creating a clear path to investigational new drug status. Also continues to expand its industrial and academic collaborations, allowing for the initiation of company’s antibody selections and proof-of-concept studies for two additional therapeutic programmes. Chief Executive Tiffany Thorn says: ‘We remain focused on developing our lead asset, BVX001, and are making great progress. At the same time, we are exploring the breadth of our Bi-Cygni approach across a wide array of different cancer types through our broad pipeline of anti-cancer therapeutic assets, which includes BVX002 and BVX003, and are applying our learnings to each of our programmes.’
----------
Copyright 2022 Alliance News Limited. All Rights Reserved.
